Bortezomib mediated BRCAness in Myeloma cells: novel therapeutic approach combining PARP1-2 and 26S proteasome inhibitors.

硼替佐米介导骨髓瘤细胞中的 BRCA：结合 PARP1-2 和 26S 蛋白酶体抑制剂的新型治疗方法。

• 批准号: 248595
• 负责人: Bahlis Nizar J
• 金额: --
• 依托单位: University of Calgary
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2011
• 资助国家: 加拿大
• 起止时间: 2011-09-01 至 2012-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=248595&lang=en
• 关键词: Multiple Myeloma; Parp And Dna Repair; Phase I Clinical Trial; Proteasome Inhibitors

Multiple myeloma is the second most common form of blood cancers and remains incurable despite the addition of novel therapeutic agents to the treatment armamentarium for this disease. As such, while the proteasome inhibitor Bortezomib has significantly i

多发性骨髓瘤是第二种最常见的血癌形式，尽管向这种疾病的治疗设备中添加了新的治疗剂，但仍然无法治愈。因此，虽然蛋白酶体抑制剂Bortez具有显著的抗肿瘤作用，